GGrantIndex
← Leaderboards

Ratna K Vadlamudi

South Texas Veterans Health Care System

Google Scholar ↗PubMed ↗ORCID ↗
$13,856,484
Attributed
$27,214,468
Total exposure
18
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.8M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$27,214,468 · 16
VA$0 · 2

By mechanism

R01$22,411,698 · 11
R44$1,997,586 · 1
T32$1,661,035 · 1
R56$915,177 · 2
P30$228,972 · 1
I01$0 · 2

Top collaborators

Others in their field

Top investigators on “Tumor”

Research focus

TumorResistanceTherapy ResistantSignal TransductionInnovationMediatingMalignant NeoplasmsGrowthMolecularGenomicsProteinsPlayNeoplasm MetastasisNovel TherapeuticsMalignant Breast NeoplasmPharmaceutical PreparationsToxic EffectChemotherapyIn VitroLeadResponseEstrogensXenograft ProcedureTumor Progression

Grant awards (85)

Development of new therapeutic approaches for endometrial cancer$709,125
R01 · FY2025 · CA
Novel targeted therapy for treating Ovarian Cancer$658,621
R01 · FY2025 · CA · contact PI
South Texas Medical Scientist Training Program (STX-MSTP)$548,831
T32 · FY2025 · GM
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$530,240
R01 · FY2025 · CA · contact PI
Enhancing endoplasmic reticulum stress in ovarian cancer$526,459
R01 · FY2025 · CA · contact PI
Mays Cancer Center at UT Health SA$66,054
P30 · FY2025 · CA · contact PI
Targeting PELP1 oncogenic functions in DNA repair for treating triple negative breast cancer$0
I01 · FY2025 · VA · contact PI
Novel targeted therapy for treating Ovarian Cancer$639,397
R01 · FY2024 · CA · contact PI
South Texas Medical Scientist Training Program (STX-MSTP)$566,455
T32 · FY2024 · GM
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$502,525
R01 · FY2024 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$377,821
R01 · FY2024 · CA
Development of new therapeutic approaches for endometrial cancer$336,835
R01 · FY2024 · CA
Enhancing endoplasmic reticulum stress in ovarian cancer$283,533
R01 · FY2024 · CA · contact PI
Mays Cancer Center at UT Health SA$32,587
P30 · FY2024 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$9,628
R01 · FY2024 · CA
Targeting PELP1 oncogenic functions in DNA repair for treating triple negative breast cancer$0
I01 · FY2024 · VA · contact PI
Novel targeted therapy for treating Ovarian Cancer$646,388
R01 · FY2023 · CA · contact PI
Enhancing endoplasmic reticulum stress in ovarian cancer$625,549
R01 · FY2023 · CA · contact PI
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma$548,472
R01 · FY2023 · CA · contact PI
South Texas Medical Scientist Training Program (STX-MSTP)$545,749
T32 · FY2023 · GM
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$390,054
R01 · FY2023 · CA
Development of new therapeutic approaches for endometrial cancer$347,471
R01 · FY2023 · CA
The role of hyaluronic acid and its receptors in the pathogenesis of endometriosis$299,804
R56 · FY2023 · HD
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$65,662
R01 · FY2023 · CA
Mays Cancer Center at UT Health SA$32,587
P30 · FY2023 · CA · contact PI
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer$0
I01 · FY2023 · VA · contact PI
Targeting mutant estrogen receptor driven breast cancers$1,015,476
R44 · FY2022 · CA
Novel targeted therapy for treating Ovarian Cancer$689,000
R01 · FY2022 · CA · contact PI
Enhancing endoplasmic reticulum stress in ovarian cancer$666,952
R01 · FY2022 · CA · contact PI
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$574,038
R01 · FY2022 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$390,354
R01 · FY2022 · CA
Development of new therapeutic approaches for endometrial cancer$354,563
R01 · FY2022 · CA
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$41,668
R01 · FY2022 · CA
Mays Cancer Center at UT Health SA$32,587
P30 · FY2022 · CA · contact PI
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer$0
I01 · FY2022 · VA · contact PI
Targeting mutant estrogen receptor driven breast cancers$982,110
R44 · FY2021 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$585,712
R01 · FY2021 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$416,086
R01 · FY2021 · CA
Mays Cancer Center at UT Health SA$32,587
P30 · FY2021 · CA · contact PI
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer$0
I01 · FY2021 · VA · contact PI
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$585,752
R01 · FY2020 · CA · contact PI
FoXM1 inhibition: a novel therapeutic avenue to treat breast cancers$429,261
R01 · FY2020 · CA
Mays Cancer Center at UT Health SA$32,570
P30 · FY2020 · CA · contact PI
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer$0
I01 · FY2020 · VA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$615,373
R56 · FY2019 · NS
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$568,179
R01 · FY2019 · CA · contact PI
Brain Aromatase in Neurological Function and Disease$354,868
R01 · FY2019 · NS
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$335,582
R01 · FY2019 · CA
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$74,623
R01 · FY2019 · CA · contact PI
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$612,002
R01 · FY2018 · CA · contact PI
Brain Aromatase in Neurological Function and Disease$354,868
R01 · FY2018 · NS
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$345,962
R01 · FY2018 · CA
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2018 · CA · contact PI
Therapeutic agents targeting nuclear receptor signaling in distinct molecular subtypes of breast cancer$38,768
R01 · FY2018 · CA · contact PI
Brain Aromatase in Neurological Function and Disease$354,868
R01 · FY2017 · NS
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$345,853
R01 · FY2017 · CA
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2017 · CA · contact PI
Brain Aromatase in Neurological Function and Disease$354,868
R01 · FY2016 · NS
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$351,000
R01 · FY2016 · CA
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2016 · CA · contact PI
Brain Aromatase in Neurological Function and Disease$359,873
R01 · FY2015 · NS
miRNAs:Safe and effective therapeutic adjuvants for treating drug resistant TNBC$349,847
R01 · FY2015 · CA
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2015 · CA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$312,617
R01 · FY2014 · NS
Novel ERbeta agonists for the treatment of gliomas$310,213
R01 · FY2014 · CA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$304,723
R01 · FY2013 · NS
PELP1, a Novel Regulator of Estrogen Receptor$242,413
R01 · FY2013 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$47,647
R01 · FY2013 · CA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$315,775
R01 · FY2012 · NS
PELP1, a Novel Regulator of Estrogen Receptor$257,887
R01 · FY2012 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$29,296
R01 · FY2012 · CA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$315,775
R01 · FY2011 · NS
PELP1, a Novel Regulator of Estrogen Receptor$257,887
R01 · FY2011 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$51,387
R01 · FY2011 · CA · contact PI
Mechanisms of Estrogen Signaling and Neuroprotection$332,500
R01 · FY2010 · NS
PELP1, a Novel Regulator of Estrogen Receptor$265,863
R01 · FY2010 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$42,360
R01 · FY2010 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$265,341
R01 · FY2009 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$253,773
R01 · FY2006 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$51,499
R01 · FY2006 · CA · contact PI
PELP1, a Novel Regulator of Estrogen Receptor$146,000
R01 · FY2005 · CA
PELP1, a Novel Regulator of Estrogen Receptor$98,003
R01 · FY2005 · CA
PELP1, a Novel Regulator of Estrogen Receptor$254,540
R01 · FY2004 · CA
PELP1, a Novel Regulator of Estrogen Receptor$14,240
R01 · FY2004 · CA
PELP1, a Novel Regulator of Estrogen Receptor$268,780
R01 · FY2003 · CA